Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

Adam M. Petrich, Joseph A. Sparano, Samir Parekh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

Original languageEnglish (US)
Article number403648
JournalAdvances in Hematology
Volume2012
DOIs
StatePublished - 2012

Fingerprint

AIDS-Related Lymphoma
Burkitt Lymphoma
HIV
Drug Therapy
Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Acquired Immunodeficiency Syndrome
Monoclonal Antibodies
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma. / Petrich, Adam M.; Sparano, Joseph A.; Parekh, Samir.

In: Advances in Hematology, Vol. 2012, 403648, 2012.

Research output: Contribution to journalArticle

@article{e97b74466bea4557a2e8784060bb9403,
title = "Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma",
abstract = "Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.",
author = "Petrich, {Adam M.} and Sparano, {Joseph A.} and Samir Parekh",
year = "2012",
doi = "10.1155/2012/403648",
language = "English (US)",
volume = "2012",
journal = "Advances in Hematology",
issn = "1687-9104",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

AU - Petrich, Adam M.

AU - Sparano, Joseph A.

AU - Parekh, Samir

PY - 2012

Y1 - 2012

N2 - Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

AB - Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84861024042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861024042&partnerID=8YFLogxK

U2 - 10.1155/2012/403648

DO - 10.1155/2012/403648

M3 - Article

VL - 2012

JO - Advances in Hematology

JF - Advances in Hematology

SN - 1687-9104

M1 - 403648

ER -